| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The molecular target of Peptide M has not been definitively identified in the available literature. As a research peptide, it may interact with specific receptors, enzymes, or cellular targets depending on its sequence and design. Further characterization is required to establish its precise mechanism of action.
|
|---|---|
| ln Vitro |
Human peptide M is immunogenic, which lends credence to the theory that human uveitis diseases may be associated with the amino acid sequence that corresponds to peptide M [1].
In vitro activity data for Peptide M are not extensively reported in the available literature. As a research peptide, it may exhibit specific biological activities such as receptor binding, enzyme inhibition, or modulation of cellular signaling pathways depending on its sequence and intended application. |
| ln Vivo |
In vivo activity data for Peptide M are not available in the literature. As a research-use peptide, it has not been extensively characterized in animal models. Further studies would be required to evaluate its in vivo efficacy and pharmacological properties.
|
| Enzyme Assay |
In vitro receptor binding assays for Peptide M would depend on its specific target. Typical assays involve incubating radiolabeled or fluorescently labeled peptide with target receptors or membrane preparations, followed by measurement of binding affinity using scintillation counting, fluorescence polarization, or surface plasmon resonance.
|
| Cell Assay |
Cell-based assays for Peptide M would be designed based on its suspected biological activity. Cells are treated with the peptide at various concentrations (typically 0.1 nM to 100 uM) for defined periods. Endpoints may include cell viability (MTT assay), receptor activation (calcium flux, cAMP accumulation), or downstream signaling (Western blot), depending on the peptide's function.
|
| Animal Protocol |
In vivo animal protocols for Peptide M are not established in the literature. As a research peptide, it could potentially be evaluated in relevant animal models depending on its biological activity. Specific dosing routes, schedules, and endpoints have not been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Peptide M are not available in the literature. As a peptide, it is expected to have limited oral bioavailability and a short half-life due to proteolytic degradation. The compound is typically stored as a lyophilized powder at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Peptide M are not available. As a research peptide, standard safety assessments would be required for therapeutic development. The compound is for research use only and not for human therapeutic application.
|
| References | |
| Additional Infomation |
Peptide M is a research-use compound not approved for clinical therapeutic applications. Due to limited available information, its specific biological activities and applications remain to be fully characterized. It is for research use only and not for human therapeutic application.
|
| Molecular Formula |
C81H141N21O31
|
|---|---|
| Molecular Weight |
1905.11
|
| Exact Mass |
1904.01
|
| CAS # |
110652-62-5
|
| PubChem CID |
16208244
|
| Appearance |
White to off-white solid powder
|
| LogP |
-14.2
|
| Hydrogen Bond Donor Count |
30
|
| Hydrogen Bond Acceptor Count |
34
|
| Rotatable Bond Count |
66
|
| Heavy Atom Count |
133
|
| Complexity |
3960
|
| Defined Atom Stereocenter Count |
23
|
| SMILES |
CC[C@@H]([C@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CC(O)=O)=O)[C@H](O)C)=O)CC(N)=O)=O)CC(C)C)=O)C)=O)CO)=O)CO)=O)[C@H](O)C)=O)[C@H](CC)C)=O)[C@H](CC)C)=O)CCCCN)=O)CCC(O)=O)=O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)C(C)C)=O)[C@H](O)C)=O)CCCCN)=O)CC(O)=O)=O)C
|
| InChi Key |
BHGSMPANCMIOOB-HMAOBDLHSA-N
|
| InChi Code |
InChI=1S/C81H141N21O31/c1-15-37(8)59(75(126)93-50(31-57(114)115)72(123)88-46(23-19-21-27-83)69(120)101-63(42(13)106)79(130)97-58(36(6)7)81(132)133)96-54(109)32-86-67(118)47(24-25-55(110)111)89-68(119)45(22-18-20-26-82)90-76(127)60(38(9)16-2)98-77(128)61(39(10)17-3)99-80(131)64(43(14)107)102-74(125)52(34-104)95-73(124)51(33-103)94-65(116)40(11)87-70(121)48(28-35(4)5)91-71(122)49(30-53(85)108)92-78(129)62(41(12)105)100-66(117)44(84)29-56(112)113/h35-52,58-64,103-107H,15-34,82-84H2,1-14H3,(H2,85,108)(H,86,118)(H,87,121)(H,88,123)(H,89,119)(H,90,127)(H,91,122)(H,92,129)(H,93,126)(H,94,116)(H,95,124)(H,96,109)(H,97,130)(H,98,128)(H,99,131)(H,100,117)(H,101,120)(H,102,125)(H,110,111)(H,112,113)(H,114,115)(H,132,133)/t37-,38-,39-,40-,41+,42+,43+,44-,45-,46-,47-,48-,49-,50-,51-,52-,58-,59-,60-,61-,62-,63-,64-/m0/s1
|
| Chemical Name |
(4S)-4-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5249 mL | 2.6245 mL | 5.2490 mL | |
| 5 mM | 0.1050 mL | 0.5249 mL | 1.0498 mL | |
| 10 mM | 0.0525 mL | 0.2625 mL | 0.5249 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
